Pharmalot Alex Hogan and Ed Silverman STAT Plus: Watch: Blockbuster drug Humira has new competition. Here’s why that matters
Pharmalot Ed Silverman STAT Plus: Debates over biosimilar uptake notwithstanding, sales growth should accelerate by 2024
